BrainStorm Cell Therapeutics Inc.
BCLI:NASDAQ
BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. The company is in a Phase 2 trial in ALS after having seen excellent safety and efficacy in earlier clinical studies.
Streetwise Company Fact Sheet
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
